Retraction Note: Receptor tyrosine kinase inhibitor Sunitinib and integrin antagonist peptide HM-3 show similar lipid raft dependent biphasic regulation of tumor angiogenesis and metastasis | Journal of Experimental & Clinical Cancer Research | Full Text

Retraction Note: Receptor tyrosine kinase inhibitor Sunitinib and integrin antagonist peptide HM-3 show similar lipid raft dependent biphasic regulation of tumor angiogenesis and metastasis | Journal of Experimental & Clinical Cancer Research | Full Text

Retraction Note: Receptor tyrosine kinase inhibitor Sunitinib and integrin antagonist peptide HM-3 show similar lipid raft dependent biphasic regulation of tumor angiogenesis and metastasis

The authors have retracted this article [1] because the bands shown in Fig. 5 panel D for GTP-RhoA/Control, GTP-RhoA/Sunitinib (2 and 64 nM) and GTP-RhoA/HM-3 (4.5 and 72 uM) are not data generated as part of ...

Authors:Jialiang Hu, Wenjing Wang, Chen Liu, Mengwei Li, Edouard Nice and Hanmei Xu

Citation:Journal of Experimental & Clinical Cancer Research 2020 39:35

Content type:Retraction Note

Published on: 17 February 2020

The original article was published in Journal of Experimental & Clinical Cancer Research 2019 38:381

• ViewFull Text
 
• ViewPDF